External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
Two nomograms have been developed to predict the outcome of positron emission tomography (PET)/computed tomography (CT) imaging with68Ga-labeled ligands for prostate-specific membrane antigen (68Ga-PSMA) for patients with rising prostate-specific antigen after radical prostatectomy (RP). These nomog...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | European Urology Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168321000756 |
| _version_ | 1818651774884511744 |
|---|---|
| author | Henk B. Luiting Sebastiaan Remmers Dennie Meijer André N. Vis Maarten Donswijk Daniela E. Oprea-Lager Louise Emmett Isabel Rauscher Henk G. Van der Poel Monique J. Roobol Pim J. van Leeuwen |
| author_facet | Henk B. Luiting Sebastiaan Remmers Dennie Meijer André N. Vis Maarten Donswijk Daniela E. Oprea-Lager Louise Emmett Isabel Rauscher Henk G. Van der Poel Monique J. Roobol Pim J. van Leeuwen |
| author_sort | Henk B. Luiting |
| collection | DOAJ |
| description | Two nomograms have been developed to predict the outcome of positron emission tomography (PET)/computed tomography (CT) imaging with68Ga-labeled ligands for prostate-specific membrane antigen (68Ga-PSMA) for patients with rising prostate-specific antigen after radical prostatectomy (RP). These nomograms quantify the ability of PSMA PET/CT to detect prostate cancer recurrences, and therefore provide critical information in determining the optimal timing for PSMA PET/CT in guiding salvage therapies. We validated the ability of these nomograms to accurately predict PET/CT outcome using another ligand tracer, 18F-DCFPyL. The external validation cohort consisted of 157 men from the Prostate Cancer Network Netherlands who underwent 18F-DCFPyL PET/CT to guide salvage therapies after RP. The nomogram of Rauscher et al (predicting a positive scan) showed accurate prediction of 50–80% (discrimination 0.68, 95% confidence interval [CI] 0.59–0.76). The nomogram of Luiting et al (predicting recurrence outside the prostatic fossa) showed accurate prediction for predicted probability values between 15% and 65%, with a small degree of overestimation for predicted probability values between 30% and 50% (discrimination 0.74, 95% CI 0.28–1.24). According to calibration curves, discrimination results, and decision curve analysis, we conclude that clinicians can use these 68Ga-PSMA–based nomograms to predict 18F-DCFPyL PET/CT outcome. These nomograms improve shared decision-making in determining the optimal time to initiate PSMA PET/CT–guided salvage therapies. Patient summary: Prediction tools developed for prostate scans (positron emission tomography, PET) using one type of radioactive tracer (chemicals labeled with gallium-68) are also accurate in predicting scan findings with another tracer (a chemical labeled with fluorine-18). Our study confirms that these tools can be used to guide decisions on the timing of treatments for prostate cancer recurrence. |
| first_indexed | 2024-12-17T02:11:28Z |
| format | Article |
| id | doaj.art-9399079cf4e14e96b029794c1d84b694 |
| institution | Directory Open Access Journal |
| issn | 2666-1683 |
| language | English |
| last_indexed | 2024-12-17T02:11:28Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Urology Open Science |
| spelling | doaj.art-9399079cf4e14e96b029794c1d84b6942022-12-21T22:07:31ZengElsevierEuropean Urology Open Science2666-16832021-06-01284751External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?Henk B. Luiting0Sebastiaan Remmers1Dennie Meijer2André N. Vis3Maarten Donswijk4Daniela E. Oprea-Lager5Louise Emmett6Isabel Rauscher7Henk G. Van der Poel8Monique J. Roobol9Pim J. van Leeuwen10Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands; Corresponding author. Department of Urology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Tel. +31 10 7032243.Department of Urology, Erasmus University Medical Center, Rotterdam, The NetherlandsDepartment of Urology, Amsterdam University Medical Center, VU University, Prostate Cancer Network Netherlands, Amsterdam, The Netherlands; Department of Radiology & Nuclear Medicine, Amsterdam University Medical Center, VU University, Cancer Center Amsterdam, Amsterdam, The NetherlandsDepartment of Urology, Amsterdam University Medical Center, VU University, Prostate Cancer Network Netherlands, Amsterdam, The Netherlands; Department of Urology, The Netherlands Cancer Institute, Prostate Cancer Network Netherlands, Amsterdam, The NetherlandsDepartment of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Radiology & Nuclear Medicine, Amsterdam University Medical Center, VU University, Cancer Center Amsterdam, Amsterdam, The NetherlandsDepartment of Theranostics and Nuclear Medicine, St Vincent’s Hospital, Sydney, AustraliaDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, GermanyDepartment of Urology, The Netherlands Cancer Institute, Prostate Cancer Network Netherlands, Amsterdam, The NetherlandsDepartment of Urology, Erasmus University Medical Center, Rotterdam, The NetherlandsDepartment of Urology, The Netherlands Cancer Institute, Prostate Cancer Network Netherlands, Amsterdam, The NetherlandsTwo nomograms have been developed to predict the outcome of positron emission tomography (PET)/computed tomography (CT) imaging with68Ga-labeled ligands for prostate-specific membrane antigen (68Ga-PSMA) for patients with rising prostate-specific antigen after radical prostatectomy (RP). These nomograms quantify the ability of PSMA PET/CT to detect prostate cancer recurrences, and therefore provide critical information in determining the optimal timing for PSMA PET/CT in guiding salvage therapies. We validated the ability of these nomograms to accurately predict PET/CT outcome using another ligand tracer, 18F-DCFPyL. The external validation cohort consisted of 157 men from the Prostate Cancer Network Netherlands who underwent 18F-DCFPyL PET/CT to guide salvage therapies after RP. The nomogram of Rauscher et al (predicting a positive scan) showed accurate prediction of 50–80% (discrimination 0.68, 95% confidence interval [CI] 0.59–0.76). The nomogram of Luiting et al (predicting recurrence outside the prostatic fossa) showed accurate prediction for predicted probability values between 15% and 65%, with a small degree of overestimation for predicted probability values between 30% and 50% (discrimination 0.74, 95% CI 0.28–1.24). According to calibration curves, discrimination results, and decision curve analysis, we conclude that clinicians can use these 68Ga-PSMA–based nomograms to predict 18F-DCFPyL PET/CT outcome. These nomograms improve shared decision-making in determining the optimal time to initiate PSMA PET/CT–guided salvage therapies. Patient summary: Prediction tools developed for prostate scans (positron emission tomography, PET) using one type of radioactive tracer (chemicals labeled with gallium-68) are also accurate in predicting scan findings with another tracer (a chemical labeled with fluorine-18). Our study confirms that these tools can be used to guide decisions on the timing of treatments for prostate cancer recurrence.http://www.sciencedirect.com/science/article/pii/S2666168321000756Prostatic neoplasmsProstate-specific membrane antigenPositron emission tomography/computed tomographyNomogramsBiochemical recurrenceProstatectomy |
| spellingShingle | Henk B. Luiting Sebastiaan Remmers Dennie Meijer André N. Vis Maarten Donswijk Daniela E. Oprea-Lager Louise Emmett Isabel Rauscher Henk G. Van der Poel Monique J. Roobol Pim J. van Leeuwen External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? European Urology Open Science Prostatic neoplasms Prostate-specific membrane antigen Positron emission tomography/computed tomography Nomograms Biochemical recurrence Prostatectomy |
| title | External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? |
| title_full | External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? |
| title_fullStr | External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? |
| title_full_unstemmed | External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? |
| title_short | External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? |
| title_sort | external validation of two nomograms developed for 68ga psma 11 applied to the prostate specific membrane antigen tracer 18f dcfpyl is prediction of the optimal timing of salvage therapy feasible |
| topic | Prostatic neoplasms Prostate-specific membrane antigen Positron emission tomography/computed tomography Nomograms Biochemical recurrence Prostatectomy |
| url | http://www.sciencedirect.com/science/article/pii/S2666168321000756 |
| work_keys_str_mv | AT henkbluiting externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT sebastiaanremmers externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT denniemeijer externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT andrenvis externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT maartendonswijk externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT danielaeoprealager externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT louiseemmett externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT isabelrauscher externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT henkgvanderpoel externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT moniquejroobol externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible AT pimjvanleeuwen externalvalidationoftwonomogramsdevelopedfor68gapsma11appliedtotheprostatespecificmembraneantigentracer18fdcfpylispredictionoftheoptimaltimingofsalvagetherapyfeasible |